Genetic markers of increased susceptibility to diabetic nephropathy

Hormone Research

Volumn 50, Issue SUPPL. 1, 1998, Pages 6-11

  Doria, Alessandro ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Aldose reductase; Angiotensin I converting enzyme; Angiotensin II receptor; Angiotensinogen; Diabetic nephropathy; DNA polymorphisms; Genetics; Insulin dependent diabetes mellitus

Indexed keywords

ALDEHYDE REDUCTASE; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENETIC LINKAGE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; HYPERGLYCEMIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

DIABETIC NEPHROPATHIES; GENETIC MARKERS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; POLYMERS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031780102     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053095     Document Type: Conference Paper

References (31)

1. Krolewski AS, Warram JH: Epidemiology of late complications of diabetes; in Kahn CR, Weir G (eds): Joslin's Diabetes mellitus, ed 13. Philadelphia, Lea & Febiger, 1994.
2. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradely RF, Kahn CR: Magnitude and determinants of coronary artery disease in juvenile-onset insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-755.
3. Krolewski AS, Laffel LMB. Krolewski M, Quinn M, Warram JH: Glycated hemoglobin and risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1252-1255.
4. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
5. Doria A, Warram JH, Krolewski AS: Genetic susceptibility to nephropathy in IDDM: From epidemiology to molecular genetics. Diabetes Metab Rev 1995;11:287-314.
6. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy: N Engl J Med 1989;320:1161-1165.
7. Borch-Johnsen, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH: Is diabetic nephropathy an inherited complication? Kidney Int 1992;41:719-722.
8. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996;39:940-945.
9. Ballerman BJ, Zeidel ML, Gunning ME, Brenner BM: Vasoactive peptides and the kidney; in Brenner BM, Rector FC (eds): The Kidney, ed 4. Philadelphia, Saunders, 1991, pp 510-583.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
11. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P: Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992;71:169-180.
12. Caulfield M, Lavender P, Newell-Price J, Farral M, Kamdar S, Daniel H, Lawson M, De Freitas P, Fogarty P, Clark AJL: Linkage of the angiotensinogen gene locus to essential hypertension in African Caribbeans. J Clin Invest 1995;96:687-692.
13. Inoue U, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997;99: 1786-1797.
14. Doria A, Onuma T, Gearin G, Freire MB, Warram JH, Krolewski AS: Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension 1996;27:1134-1139.
15. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, Poirier O, Parving HH: Angiotensinogen gene polymorphism in IDDM patients with diabetic nephropathy. Diabetes 1996;45:367-369.
16. Fogarty DG, Harron JC, Hughes AE, Nevin NC, Doherty CC, Maxwell AP: A molecular variant of angiotensinogen is associated with diabetic nephrophathy in IDDM. Diabetes 1996;45:1204-1208.
17. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin-I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86: 1343-1346.
18. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion polymorphism in the gene for angiolensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
19. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels and diabetic retinal and renal complications. Diabetes 1994;43:384-388.
20. Barnas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, Irsigler K, Mayer G: Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme polymorphism, hypertension, and metabolic control. Diabetologia 1997:40:327-331.
21. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH: Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995;44:489-494.
22. Schmidt S, Schone N, Ritz E, and the Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int 1995;47:1176-1181.
23. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy: Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994;43:690-695.
24. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow-up study. Br Med J 1996;313:591-594.
25. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F: Angiotensin II type I receptor gene polymorphism in human essential hypertension. Hypertension 1994;24:63-69.
26. Doria A, Onuma T, Warram JH, Krolewski AS: Synergistic effect of angiotensin II receptor genotype and poor glycemic control on risk of nephropathy in IDDM. Diabetologia 1997;40: 1293-1299.
27. Heesom AE, Hibberd ML, Millward A, Demaine AG: Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 1997;46:287-291.
28. Moczulski D, Rogus JJ, Warram JH, Krolewski AS: Exclusion of aldose reductase (AR) gene as a major locus for diabetic nephropathy in IDDM: Results of family-based studies. Diabetes 1997;46:171A.
29. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus. Am J Hum Genet 1993;52: 506-516.
30. Brownlee M: Glycation and diabetic complications. Diabetes 1994;43:836-840.
31. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YE, Tsang TC, Stern D: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial surface. J Biol Chem 1992;267:14987-14997.